Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

Transplantation

Volumn 89, Issue 9, 2010, Pages 1095-1102

  Vo, Ashley A ^a   Peng, Alice ^a   Toyoda, Mieko ^a   Kahwaji, Joseph ^a   Cao, Kai ^a   Lai, Chih Hung ^a   Reinsmoen, Nancy L ^a   Villicana, Rafael ^a   Jordan, Stanley C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acute antibody mediated rejection; Acute cell mediated rejection; Alemtuzumab; Antithymocyte globulin; Daclizumab; Highly sensitized; IVIG; Kidney transplant; Rituximab

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; DIPHENHYDRAMINE; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; DESENSITIZATION; DRUG MEGADOSE; DYSPNEA; FEMALE; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECIPIENT; SEPSIS; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; AUTOANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL RATE; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 77951823581     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d21e7f     Document Type: Article

References (38)

1. Evans RW, Manninen DL, Garrison LPJ, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985; 312: 553.
2. Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
3. Russell JD, Beecroft ML, Ludwin D, et al. The quality of life in renal transplantation\A prospective study. Transplantation 1992; 54: 656.
4. Organ Procurement Transplantation Network/Scientific Registry of Transplant Recipients. 2009. Available at: http://www.optn.org/data/. Accessed September 7, 2009.
5. United Network for Organ Sharing Data Base. Available at: http://www. unos.org. Accessed May 30, 2008.
6. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
7. Reinsmoen NL, Lai CH, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86: 820.
8. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
9. Gebel H, Bray R, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488.
10. Kerman R, Gebel H, Bray R, et al. HLA antibody and donor reactivity define patients at risk for rejection or graft loss. Am J Transplant 2002; 2: 258.
11. Bearden CM, Agarwal A, Book BK, et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 2004; 65: 803.
12. Toyoda M, Puliyanda D, Amet N, et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005; 80: 198.
13. Vo AA, Toyoda M, Peng A, et al. Effects of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6: 2384.
14. Vo AA, Weschler EA, Wang J, et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144.
15. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518.
16. Jordan SC, Vo AA, Tyan D, et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005; 9: 408.
17. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57: 553.
18. Jordan SC, Toyoda M, Vo A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1.
19. Tyan D, Chen G, Sequeira F, et al. C1Q: A novel assay to detect complement fixing HLA antibody. Am J Transplant 2009; 9: 485(abstract 1041).
20. Jordan SC, Vo A, Peng A, et al. Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6: 459.
21. Jordan SC, Pescovits M. Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421.
22. Glotz D, Antoine C, Julia P, et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 2004; 17: 1.
23. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 1531.
24. Montgomery RA, Cooper M, Kraus E, et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clin Transpl 2003; 199: 213.
25. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection inrenal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998; 66: 800.
26. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immuno-globulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71: 53.
27. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid and anti-lymphocyte antibody-resistant rejection using intravenous im-munoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72: 419.
28. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chi-meric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
29. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell targeted therapy with rituximab in rheumatoid arthritis. N Engl J Med 2004; 350: 2572.
30. Salama AD, Pusey CD. Drug insight: Rituximab in renal disease in transplantation. Nat Clin Pract Nephrol 2006; 4: 221.
31. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006: 394.
32. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008; 112: 1147.
33. Liossis SN, Sfikakis PP. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin Immunol 2008; 127: 280.
34. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: Safety, pharmacody-namics, and pharmacokinetics. Transplantation 2004; 77: 542.
35. Faguer S, Kamar N, Guilebeaud-Frugier C, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 1277.
36. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772.
37. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214.
38. Nimmerjahn F, Ravetch J. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513.